Vanguard Group’s Pasithea Therapeutics KTTA Stock Holding History

Vanguard Group’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$126K	Buy	97,675 +43,860	+82%	+$38.5K	﹤0.01%	4150
2025 Q3	$38.7K	Buy	+53,815	New	+$39.3K	﹤0.01%	4314
2023 Q3	–	Sell	-6,050	Closed	-$59.3K	–	4552
2023 Q2	$59.3K	Sell	6,050 -1,960	-24%	-$15.8K	﹤0.01%	4441
2023 Q1	$60.1K	Hold	8,010	–	–	﹤0.01%	4456
2022 Q4	$103K	Buy	8,010 +18	+0.2%	+$360	﹤0.01%	4389
2022 Q3	$201K	Buy	7,992 +4,085	+105%	+$95.9K	﹤0.01%	4416
2022 Q2	$79K	Buy	3,907 +1,078	+38%	+$22.9K	﹤0.01%	4562
2022 Q1	$74K	Buy	2,829 +2,194	+346%	+$55.5K	﹤0.01%	4608
2021 Q4	$22K	Buy	+635	New	+$33K	﹤0.01%	4632

Other funds holding KTTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Vanguard Group's KTTA Position: Q4 2025 in Review

Vanguard Group increased its Pasithea Therapeutics (KTTA) stake by 82% in Q4 2025, buying an estimated $38.5K and bringing the position to 97,675 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #4150.

Vanguard Group first reported a position in KTTA in Q4 2021 and has held it in 9 quarters since. The position peaked at $201K in Q3 2022. 26 funds tracked by Wall St. Rank hold KTTA as of Q4 2025.

Vanguard Group held 97,675 shares of Pasithea Therapeutics worth $126K as of Q4 2025.
Vanguard Group bought 43,860 Pasithea Therapeutics shares in Q4 2025, an estimated $38.5K.
Pasithea Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4150 holding.
Vanguard Group first reported a position in Pasithea Therapeutics in Q4 2021 and has held it in 9 quarters since.
Vanguard Group's Pasithea Therapeutics position peaked at $201K in Q3 2022.
26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.